Dataset: Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [Mouse430_2]
U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine...
U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ) when tumour is established in BALB/c SCID mice. At the end point, collect tumour samples and extracted total RNA for microarray to investigate the gene profile changes compared to control. These include the genes from human tumour cells and mouse host stroma cells. 5 control, 5 dibenzazepine-treated, and 4 bevacizumab-treated samples
- Species:
- mouse
- Samples:
- 14
- Source:
- E-GEOD-39413
- PubMed:
- 23871637
- Updated:
- Jun.29, 2015
- Registered:
- Nov.12, 2014
Factors:
(via ArrayExpress)
| Sample | TREATED WITH |
|---|---|
| GSM967852 | phosphate buffered saline (PBS) as a control |
| GSM967852 | phosphate buffered saline (PBS) as a control |
| GSM967852 | phosphate buffered saline (PBS) as a control |
| GSM967852 | phosphate buffered saline (PBS) as a control |
| GSM967852 | phosphate buffered saline (PBS) as a control |
| GSM967857 | dibenzazepine (DBZ) (8.1mmol/kg) |
| GSM967857 | dibenzazepine (DBZ) (8.1mmol/kg) |
| GSM967857 | dibenzazepine (DBZ) (8.1mmol/kg) |
| GSM967857 | dibenzazepine (DBZ) (8.1mmol/kg) |
| GSM967857 | dibenzazepine (DBZ) (8.1mmol/kg) |
| GSM967862 | Bevacizumab (10mg/kg body weight) |
| GSM967862 | Bevacizumab (10mg/kg body weight) |
| GSM967862 | Bevacizumab (10mg/kg body weight) |
| GSM967862 | Bevacizumab (10mg/kg body weight) |